BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The important identification of the elevation of tyrosine kinase activity in BCR-ABL fusion gene in CML pathogenesis contributed in developing effective tyrosine kinase inhibitors (Druker, 2008).